MedicalFoundationOfNC.org Editorial Team | Updated April 2026
This article is for general informational purposes only and is not medical advice. Safety information below is based on the FDA-approved prescribing information for Wegovy (semaglutide) tablets as of April 2026. Consult a licensed healthcare provider with your full medical history before starting any prescription weight loss medication.
Quick Answer: The Wegovy pill carries a boxed warning — the FDA's highest alert level — regarding thyroid C-cell tumors observed in animal studies. It is contraindicated (must not be used) in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It's also not approved for anyone under 18, anyone currently pregnant or planning pregnancy within two months, or anyone taking other semaglutide products simultaneously. The most common side effects are nausea, diarrhea, and vomiting — typically worst during dose escalation and manageable for most people who follow the slow titration schedule.
Looking up the safety profile of a medication before you start it is the right move — and with the Wegovy pill now in over 400,000 Americans' hands just months after launch, a lot of people are doing exactly that. The Wegovy pill has a well-characterized safety record — it's built on over a decade of semaglutide pharmacovigilance across multiple formulations and indications — but there are specific contraindications, warnings, and medication interactions that anyone considering it should understand clearly before their first conversation with a prescriber.
This article covers what the FDA-approved prescribing information actually says about who should not take oral semaglutide, what side effects to expect, and what medical conditions require extra caution.
What Is the Wegovy Pill's Boxed Warning About?
The most prominent safety item in oral Wegovy's labeling is its boxed warning regarding thyroid C-cell tumors. In rodent studies, semaglutide caused thyroid C-cell tumors, including thyroid carcinoma, at clinically relevant exposures. Whether this risk translates to humans hasn't been definitively established — human thyroid C-cells express the GLP-1 receptor at substantially lower levels than rodent thyroid tissue — but the FDA requires the warning until human relevance is excluded.
As a result: Wegovy tablets are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These are absolute contraindications — not “use with caution” situations.
You should tell your healthcare provider promptly about any lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath while taking oral semaglutide. These can be symptoms of thyroid tumors and require evaluation.
Who Should Absolutely Not Take the Wegovy Pill?
Beyond the boxed warning, the prescribing information identifies several contraindications and high-caution situations:
Prior serious hypersensitivity to semaglutide: If you had anaphylaxis or angioedema with any semaglutide product (Ozempic, Rybelsus, injectable Wegovy), the oral formulation is also contraindicated.
Pregnancy and pregnancy planning: Semaglutide has a long half-life. The prescribing information recommends discontinuing Wegovy tablets at least two months before a planned pregnancy. Animal reproduction studies showed adverse developmental outcomes. If you become pregnant while taking oral semaglutide, discontinue it and contact your healthcare provider.
Under 18 years of age: The oral formulation has not established safety and effectiveness in anyone under 18. The injectable Wegovy is approved for adolescents 12 and older with obesity; the pill is not.
Concurrent use of other semaglutide-containing products: Wegovy tablets should not be taken alongside Ozempic, Rybelsus, injectable Wegovy, or any other GLP-1 receptor agonist. Taking multiple GLP-1 products simultaneously doesn't improve outcomes and increases risk of adverse effects.
What Are the Most Common Side Effects of the Wegovy Pill?
The most commonly reported adverse reactions with oral semaglutide in OASIS 4 were nausea, diarrhea, and vomiting — consistent with what's seen across all GLP-1 receptor agonist therapies. These are class effects, not unique to the pill formulation.
GI side effects with semaglutide are dose-dependent and most prominent during the dose escalation phase. They typically peak in the first several weeks at each new dose level and then diminish as the body adjusts. The slow titration schedule — starting at 1.5 mg for four weeks before stepping up to 4 mg, then 9 mg, then 25 mg — exists specifically to allow for GI adaptation at each level. Skipping dose escalation steps or rushing to maintenance dose is associated with worse GI tolerability.
Other commonly reported reactions include constipation, abdominal pain, and decreased appetite. Decreased appetite is typically considered a therapeutic effect rather than an adverse effect, but it can occasionally be pronounced enough to affect nutritional intake in ways that require monitoring.
What Are the Serious Risks That Require a Doctor's Awareness?
Acute pancreatitis: GLP-1 receptor agonists have been associated with acute pancreatitis, including cases that were severe, hemorrhagic, or fatal. If you develop persistent or severe abdominal pain — especially pain that radiates to the back, with or without nausea or vomiting — stop the medication and seek medical evaluation. People with a personal history of pancreatitis may not be appropriate candidates for semaglutide; discuss your history with your prescriber.
Acute gallbladder disease: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) occurred at higher rates in semaglutide-treated patients compared to placebo in clinical trials. The mechanism is related to rapid weight loss and changes in bile composition — a risk that's present with any effective weight loss treatment, not unique to GLP-1 drugs. If you develop abdominal pain in the upper right quadrant, contact your healthcare provider — this is the characteristic presentation of gallbladder problems.
Acute kidney injury: GLP-1 receptor agonists can cause dehydration through nausea, vomiting, and diarrhea — and dehydration is the primary mechanism behind the acute kidney injury events that have been reported post-market. People with existing kidney disease or conditions that already affect kidney function need additional monitoring during dose escalation, when GI side effects are most likely. Staying well-hydrated while on semaglutide is important for everyone, not only those with existing kidney concerns.
Diabetic retinopathy complications: In semaglutide trials for people with type 2 diabetes, there were more complications from diabetic retinopathy in the semaglutide group versus placebo, particularly in people with pre-existing retinopathy. If you have a history of diabetic retinopathy, inform your prescriber before starting oral semaglutide and maintain your ophthalmology monitoring schedule.
Hypoglycemia with concomitant insulin or secretagogues: Oral semaglutide by itself doesn't typically cause hypoglycemia. However, if you take insulin or sulfonylurea-class diabetes medications alongside it, the risk of hypoglycemia increases. Dose adjustments to those medications may be needed when starting semaglutide. This is a conversation for your prescriber and pharmacist.
Heart Rate Considerations
Semaglutide is associated with a modest increase in resting heart rate — on the order of 2–5 beats per minute on average in clinical trials. For most people this is clinically insignificant. If you have a history of cardiac arrhythmia or existing elevated resting heart rate, discuss this with your cardiologist or primary care provider before starting.
Is the Wegovy Pill Safer Than the Injection — or Riskier?
The safety profile of oral and injectable semaglutide is largely similar — the molecule is the same. A few differences are worth noting. Injection site reactions (redness, bruising, skin irritation) are only relevant for the injection. The oral form doesn't carry those. Conversely, the oral form's drug interaction consideration around timing is more significant: because other medications need to wait at least 30 minutes after the pill, people with complex morning medication regimens need to plan carefully, and some medications' absorption may be affected by the temporary gastric pH changes from SNAC technology.
For a complete picture of how the Wegovy pill compares to injectable GLP-1 options and other weight loss pathways for efficacy, cost, and practical considerations, our GLP-1 comparison guide covers the full current field. For the full clinical and cost breakdown on oral Wegovy specifically, see our Wegovy pill 2026 guide.
For readers evaluating telehealth-based compounded semaglutide pathways, our MEDVi platform overview covers that option and what it involves. For information on a different FDA-approved oral weight loss medication, see our Foundayo 2026 guide.
All safety information in this article comes from the FDA-approved prescribing information for Wegovy (semaglutide) tablets as of April 2026. This is not a comprehensive medical review. This is not medical advice. Consult your healthcare provider with your complete medical history before making decisions about prescription weight loss medication.